Affiliation:
1. Department of Urology, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy
Abstract
(1) Background: Laparoscopic partial nephrectomy (LPN) is still performed in many referred urological institutions, representing a valid alternative to robot-assisted partial nephrectomy (RAPN). We aimed to compare trifecta outcomes of LPN and RAPN with the Hugo™ RAS System. (2) Methods: Between October 2022 and September 2023, eighty-nine patients underwent minimally invasive partial nephrectomy (group A, RAPN = 27; group B, Laparoscopic PN = 62) for localized renal tumors at our Institution. Continuous variables were presented as median and IQR and compared by means of the Mann–Whitney U test, while categorical variables were presented as frequencies (%) and compared by means of the χ2 test. (3) Results: Group A showed a higher rate of male patients (81.5% vs. 59.7%, p = 0.04) and a higher trend towards larger clinical tumor size (34 vs. 29 mm, p = 0.14). All the other baseline variables were comparable between the two groups (all p > 0.05). Regarding post-operative data, group A displayed a lower operative time (92 vs. 149.5 min, p = 0.005) and a shorter hospital stay (3 vs. 5, p = 0.002). A higher rate of malignant pathology was evidenced in group A (77.8% vs. 58.1%, p = 0.07) as well as a lower trend towards positive surgical margins (3.7% vs. 4.8%, p = 0.82), even if not statistically significant. (4) Conclusions: The rate of trifecta achievement was 92.6% and 82.3% for group A and B (p = 0.10), respectively. In terms of trifecta outcomes, RAPN using the Hugo™ RAS System showed comparable results to LPN performed by the same experienced surgeon.
Reference33 articles.
1. Epidemiology of Renal Cell Carcinoma: 2022 Update;Bukavina;Eur. Urol.,2022
2. Triggers for delayed intervention in patients with small renal masses undergoing active surveillance: A systematic review;Campi;Minerva Urol. Nefrol.,2020
3. Napolitano, L., Orecchia, L., Giulioni, C., Carbonara, U., Tavella, G., Lizzio, L., Fimognari, D., De Palma, A., Gheza, A., and Grosso, A.A. (2023). The Role of miRNA in the Management of Localized and Advanced Renal Masses, a Narrative Review of the Literature. Appl. Sci., 13.
4. Biomarkers for Renal Cell Carcinoma Recurrence: State of the Art;Marchioni;Curr. Urol. Rep.,2021
5. Secreted miR-210-3p as non-invasive biomarker in clear cell renal cell carcinoma;Petrozza;Oncotarget,2017
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献